Loading...
XNASQNCX
Market cap82mUSD
Jan 08, Last price  
1.88USD
1D
-3.09%
1Q
161.11%
IPO
-92.12%
Name

Quince Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:QNCX chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
11.56%
Rev. gr., 5y
%
Revenues
0k
Net income
-31m
L-39.25%
-12,235,000-12,476,000-36,792,000-76,849,000-89,325,000-51,660,000-31,385,000
CFO
-18m
L-58.46%
-9,827,000-11,695,000-33,277,000-50,818,000-62,932,000-44,038,000-18,292,000
Earnings
Mar 31, 2025

Profile

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
URL
https://quincetx.com/
IPO date
May 09, 2019
Employees
55
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
27,464
51,365
Unusual Expense (Income)
NOPBT
(27,464)
(51,365)
NOPBT Margin
Operating Taxes
(197)
(284)
Tax Rate
NOPAT
(27,267)
(51,081)
Net income
(31,385)
-39.25%
(51,660)
-42.17%
Dividends
Dividend yield
Proceeds from repurchase of equity
63,881
17,111
BB yield
-163.38%
-80.14%
Debt
Debt current
64
453
Long-term debt
14,071
453
Deferred revenue
Other long-term liabilities
54,190
Net debt
(61,002)
(92,853)
Cash flow
Cash from operating activities
(18,292)
(44,038)
CAPEX
(160)
(133)
Cash from investing activities
(5,758)
18,002
Cash from financing activities
143
707
FCF
(26,251)
(51,288)
Balance
Cash
75,059
90,181
Long term investments
78
3,578
Excess cash
75,137
93,759
Stockholders' equity
(316,554)
(288,512)
Invested Capital
469,642
389,558
ROIC
ROCE
EV
Common stock shares outstanding
37,237
33,497
Price
1.05
64.73%
0.64
-94.95%
Market cap
39,099
83.13%
21,351
-94.31%
EV
(21,903)
(71,502)
EBITDA
(27,142)
(51,161)
EV/EBITDA
0.81
1.40
Interest
568
Interest/NOPBT